(a) In secondary prevention of ischemic stroke, lipid screening should be performed as early as possible in people with ischemic stroke or TIA. For all stroke patients with baseline LDL-C >100 MG/DL, statin therapy should be given as early as possible to reduce LDL-C to below 100 mg/dl. (ii) For those at very high risk of ischemic stroke or TIA recurrence (with coronary artery disease and/or diabetes mellitus and/or smoking and/or metabolic syndrome), LDL-C should be lowered to below 80 mg/dl for those with baseline LDL-C of 80 mg/dl-99 mg/dl. (iii) Intensive statin therapy is recommended for patients with ischemic stroke or TIA with definite evidence of large artery atherosclerosis requiring intervention, or for patients with ischemic stroke or TIA with evidence of arterial-arterial embolism. (iv) Long-term continuous statin therapy is recommended for patients with ischemic stroke and TIA to keep LDL-C levels within target values in the long term. (v) Available data suggest that long-term use of statins is safe, but regular monitoring of liver enzymes and muscle enzymes is required. If liver enzymes exceed the upper limit of normal by a factor of 3 and muscle enzymes exceed the upper limit of normal by a factor of 5, the drug should be discontinued for observation. If the situation improves, switch to another statin or reduce the dose on the basis of close monitoring. Use with caution in patients with a history of prior hemorrhagic stroke weighing the risks and benefits. For stroke patients requiring combination therapy with fibrates, fenofibrate is recommended. 1. Evidence of arterial-arterial embolism; 2. Clear evidence of large artery atherosclerosis.